ID16927A - Suspensi berair dari ester asam lemak 9-hidroksirisperidon - Google Patents

Suspensi berair dari ester asam lemak 9-hidroksirisperidon

Info

Publication number
ID16927A
ID16927A IDP971649A ID971649A ID16927A ID 16927 A ID16927 A ID 16927A ID P971649 A IDP971649 A ID P971649A ID 971649 A ID971649 A ID 971649A ID 16927 A ID16927 A ID 16927A
Authority
ID
Indonesia
Prior art keywords
hydroxirirperperonone
suspension
water
fatty acid
fatty
Prior art date
Application number
IDP971649A
Other languages
English (en)
Indonesian (id)
Inventor
Marc Karel Josef Francois
Roger Carolus August Embrechts
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID16927(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID16927A publication Critical patent/ID16927A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IDP971649A 1996-05-20 1997-05-19 Suspensi berair dari ester asam lemak 9-hidroksirisperidon ID16927A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
ID16927A true ID16927A (id) 1997-11-20

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971649A ID16927A (id) 1996-05-20 1997-05-19 Suspensi berair dari ester asam lemak 9-hidroksirisperidon

Country Status (37)

Country Link
US (1) US6077843A (fr)
EP (1) EP0904081B1 (fr)
JP (1) JP3274687B2 (fr)
KR (1) KR100358373B1 (fr)
CN (1) CN1093762C (fr)
AR (1) AR007194A1 (fr)
AT (1) ATE208619T1 (fr)
AU (1) AU715572B2 (fr)
BG (1) BG62684B1 (fr)
BR (1) BR9706824B8 (fr)
CA (1) CA2236691C (fr)
CY (2) CY2270B1 (fr)
CZ (1) CZ291284B6 (fr)
DE (2) DE69708284T2 (fr)
DK (1) DK0904081T3 (fr)
EA (1) EA000536B1 (fr)
EE (1) EE03594B1 (fr)
ES (1) ES2167745T3 (fr)
FR (1) FR11C0035I2 (fr)
HR (1) HRP970276B1 (fr)
HU (2) HU224025B1 (fr)
ID (1) ID16927A (fr)
IL (1) IL124551A (fr)
LU (1) LU91842I2 (fr)
MX (1) MX9804816A (fr)
MY (1) MY126302A (fr)
NO (2) NO315931B1 (fr)
NZ (1) NZ330369A (fr)
PL (1) PL188309B1 (fr)
PT (1) PT904081E (fr)
SI (1) SI0904081T1 (fr)
SK (1) SK284013B6 (fr)
TR (1) TR199800923T2 (fr)
TW (1) TW487572B (fr)
UA (1) UA61898C2 (fr)
WO (1) WO1997044039A1 (fr)
ZA (1) ZA974331B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU753278B2 (en) * 1998-02-25 2002-10-10 Abbott Laboratories Butorphanol sustained release formulations
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
HRP20010700B1 (hr) 1999-03-31 2011-01-31 Janssen Pharmaceutica N.V. Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
NZ524554A (en) * 2000-08-14 2005-07-29 Teva Pharma Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
KR100931784B1 (ko) 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP2633853A1 (fr) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Formulations d'administration à long terme et leurs procédés d'utilisation
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
BRPI0809837A2 (pt) * 2007-04-19 2014-11-11 Youxin Li "composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
KR20100099292A (ko) 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2009089076A2 (fr) * 2008-01-10 2009-07-16 Teva Pharmaceutical Industries Ltd. Procédés de préparation et de purification de palmitate de palipéridone
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
EP2341905B2 (fr) 2008-09-04 2023-09-13 Amylin Pharmaceuticals, LLC Formulations à libération prolongée à base de supports non aqueux
EP3735944A1 (fr) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (fr) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. Nouveau procédé de préparation de palipéridone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012053654A1 (fr) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Formulation à libération prolongée pour injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012164582A1 (fr) 2011-05-31 2012-12-06 Ramamohan Rao Davuluri Préparation de 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-pipéridinyl)-6, 7, 8, 9-tétrahydro-9-hydroxy-2-méthyl-4h-pyrido [ 1, 2-a]-pyrimidin-4-one (palepéridone) et de palmitate de palipéridone
WO2013046225A2 (fr) * 2011-08-10 2013-04-04 Glenmark Generics Limited Procédé de préparation de palmitate de palipéridone
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SMT202000351T1 (it) 2015-04-07 2020-09-10 Janssen Pharmaceuticals Inc Regime di dosaggio per dosi mancate per esteri di paliperidone iniettabili ad azione prolungata
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2022111859A1 (fr) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Schémas posologiques associés à des formulations injectables de palipéridone à libération prolongée
MX2023006369A (es) 2020-11-30 2023-08-09 Janssen Pharmaceutica Nv Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona.
EP4025189B1 (fr) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Schémas posologiques associés à des formulations injectables de palipéridone à libération prolongée
PL4025187T3 (pl) 2020-11-30 2024-04-29 Janssen Pharmaceutica Nv Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
US12472184B2 (en) 2021-08-20 2025-11-18 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (fr) * 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP2275089A1 (fr) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Préparastion de microparticules biodégradables contentant un agent biologiquement actif
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
ATE199147T1 (de) * 1995-06-06 2001-02-15 Aventis Pharma Inc Benzisoxazol- und indazol- derivate als antipsychotika
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
BR9706824B8 (pt) 2015-02-18
AU2955997A (en) 1997-12-09
PL327995A1 (en) 1999-01-04
BG62684B1 (bg) 2000-05-31
HUS1100013I1 (hu) 2017-03-28
KR100358373B1 (ko) 2003-02-11
AR007194A1 (es) 1999-10-13
ATE208619T1 (de) 2001-11-15
EE03594B1 (et) 2002-02-15
DE122011100027I1 (de) 2011-11-17
CN1206347A (zh) 1999-01-27
LU91842I2 (fr) 2011-09-20
CN1093762C (zh) 2002-11-06
TW487572B (en) 2002-05-21
CA2236691C (fr) 2007-01-02
PL188309B1 (pl) 2005-01-31
SI0904081T1 (en) 2002-04-30
HUP9901319A2 (hu) 1999-08-30
SK62098A3 (en) 2000-04-10
CY2011011I2 (el) 2016-12-14
MY126302A (en) 2006-09-29
BR9706824A (pt) 1999-03-23
HRP970276B1 (en) 2002-04-30
DE69708284T2 (de) 2002-07-25
ZA974331B (en) 1998-11-19
IL124551A0 (en) 1998-12-06
NO981984D0 (no) 1998-04-30
NZ330369A (en) 2000-04-28
NO2011015I2 (no) 2013-03-11
AU715572B2 (en) 2000-02-03
TR199800923T2 (xx) 1999-09-21
DE69708284D1 (de) 2001-12-20
NO2011015I1 (no) 2011-09-19
CY2270B1 (en) 2003-07-04
EP0904081A1 (fr) 1999-03-31
KR19990067603A (ko) 1999-08-25
MX9804816A (es) 1998-10-31
BG102443A (en) 1999-06-30
EE9800136A (et) 1998-10-15
WO1997044039A1 (fr) 1997-11-27
IL124551A (en) 2001-08-26
EA000536B1 (ru) 1999-10-28
FR11C0035I2 (fr) 2013-08-16
CY2011011I1 (el) 2016-12-14
NO981984L (no) 1998-11-19
HK1017852A1 (en) 1999-12-03
HU224025B1 (hu) 2005-05-30
JP2000513718A (ja) 2000-10-17
US6077843A (en) 2000-06-20
HRP970276A2 (en) 1998-04-30
CA2236691A1 (fr) 1997-11-27
HUP9901319A3 (en) 1999-11-29
CZ140198A3 (cs) 1999-04-14
SK284013B6 (sk) 2004-08-03
UA61898C2 (en) 2003-12-15
FR11C0035I1 (fr) 2011-07-10
JP3274687B2 (ja) 2002-04-15
ES2167745T3 (es) 2002-05-16
EP0904081B1 (fr) 2001-11-14
NO315931B1 (no) 2003-11-17
EA199800531A1 (ru) 1998-12-24
CZ291284B6 (cs) 2003-01-15
DK0904081T3 (da) 2002-02-25
PT904081E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
ID16927A (id) Suspensi berair dari ester asam lemak 9-hidroksirisperidon
ID24981A (id) Suspensi berair dari ester-ester asam lemak 9-hidroksirisperidon submikron
ID15886A (id) Pembuatan alkil ester secara kontiniu dari asam met-akrilik
ID16433A (id) Penyediaan kontinyu alkil ester dari asam (met)akrilat
FI963867A7 (fi) Rasvahappoestereiden käyttö bioadhesiivisina aineina
ID18276A (id) Metoda pembuatan ester asam lemak
ID15885A (id) Pembuatan alkil ester secara kontiniu dari asam met-akrilik
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
ID19514A (id) Penggunaan dari kondesasi asam formaldehid naftallenasulfat sebagai pembantu pengeringan
ID22095A (id) Asam aril-akrilat ester
ID27724A (id) Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya
ID26359A (id) Perbaikan proses untuk memperoleh kembali ksanthophil dari zat perekat tepung jagung
DE69922309D1 (de) Verfahren zur Herstellung von Fettsäureestern
ID17679A (id) Penggunaan dari kondensasi asam formaldehid naftalenasulfat sebagai pembantu pengeringan
ID21753A (id) Proses pembuatan asam asetat
DE69712890D1 (de) Herstellung von sorbitan-fettsäureestern als oberflächenaktive stoffe
DE59913680D1 (de) Fettsäurepartialester von Polyolen
ATE216359T1 (de) Sulfonsäureester von duftstoffen
DE69608883D1 (de) Neue verwendung von fettsäurealkylestern
EP0673914A3 (fr) Préparation d'esters d'alpha-céto-acides.
ID17993A (id) Pembuatan alkil ester dari asam (meth) akrilik
FR2757165B1 (fr) Ester de l'acide maleimidobenzoique
ID22832A (id) Metode pembuatan asam formilfosfonat
ID20291A (id) Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa
DE59812612D1 (de) Enzymatische Herstellung von regioselektiven Fettsäureestern der Ascorbinsäure